

Food and Drug Administration Rockville MD 20857

April 1, 2002

John R. Polito Smoking Cessation Instructor 709 Black Oak Blvd. Summerville, South Carolina 29485

Dear. Mr. Polito:

I writing in response to your emails to Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research, regarding studies completed for nicotine replacement therapy (NRT).

The information you have provided is being evaluated by both the Division of Over-the-Counter (OTC) Drug Products and Division of Anesthetic, Critical Care, and Addiction Drug Products.

Once they have evaluated the data you have provided regarding OTC NRT studies they will provide you with a detailed response of their findings.

If you have any further questions prior to receipt of our findings please contact me at my office, (301) 594-6779 or email lemleyl@cder.fda.gov. Thank you for writing to the Food and Drug Administration.

Sincerely,

Lee Lemley

Policy Analyst

Executive Operations Staff (HFD-006) Center for Drug Evaluation and Research CDER Log No 2002-5629

Cc: HFD-560 (Katz/Cothran) HFD-170 (McCormick)

Drafted: Llemley 4/1/02 Concur: Kroberts 4/1/02